NAD+ (nicotinamide adenine dinucleotide) is a molecule your cells use to produce energy, repair DNA, and regulate dozens of critical biological processes. In addiction, chronic drug or alcohol use depletes NAD+ levels, leaving cells damaged and struggling to function normally. The theory behind NAD+ therapy is straightforward: replenish what substances have drained, and the brain and body can begin recovering faster, with fewer cravings and milder withdrawal. Early clinical data supports parts of this idea, though the evidence base is still small and the treatment is not FDA-approved.
Why Addiction Depletes NAD+
Every cell in your body depends on NAD+ to convert food into usable energy. It is also a key substrate for enzymes called sirtuins and ADP-ribosyltransferases, which repair damaged DNA, regulate gene expression, and control cell survival pathways. When you flood your system with alcohol, opioids, or stimulants over weeks or months, the resulting oxidative stress burns through NAD+ reserves faster than your body can replenish them.
The consequences cascade. With less NAD+ available, neurons struggle to repair the DNA damage caused by substance-related oxidative stress. Energy production in the brain drops. The cellular machinery that supports mood regulation, impulse control, and the brain’s natural reward system starts to malfunction. This is one reason why withdrawal feels so brutal: your cells are running on empty at the exact moment they need the most energy to heal.
What NAD+ Therapy Looks Like
Most addiction-focused NAD+ therapy is delivered intravenously. A typical protocol, based on early clinical work dating back to 1961 and still used in similar forms today, involves 500 to 1,000 mg of NAD+ mixed into a saline drip, administered daily for about four days. After the initial loading phase, infusions taper to twice per week for roughly a month, then shift to a maintenance schedule of twice per month until the treatment team determines the patient has stabilized.
Each infusion session can last several hours because the drip rate needs to be slow. Patients sometimes report discomfort during infusions, including nausea, chest tightness, or a flushed feeling if the rate is too fast. The FDA has also flagged adverse events associated with compounded NAD+ products, including low blood pressure, uncontrollable shaking, and body aches during or shortly after administration. These reactions appear to be uncommon but worth knowing about.
Effects on Cravings and Withdrawal
The most consistent finding across NAD+ addiction research is a reduction in cravings and withdrawal severity. A pilot study from UT Health San Antonio involving 50 patients with substance use disorder measured outcomes before and after IV NAD+ infusions and found statistically significant reductions in craving scores, anxiety, and depression. The improvements followed a dose-dependent pattern, meaning more infusions produced progressively better results. A urine analysis conducted on 40 of those patients midway through the study found zero positive results for illicit substances.
Earlier case reports described similar results. Dr. Paul O’Hollaren published a retrospective series in 1961 documenting 104 cases of addiction to alcohol, heroin, morphine, cocaine, amphetamines, and barbiturates treated with IV NAD+. He reported that patients were able to stop using addictive drugs without experiencing what he called the “agony of withdrawal.” Those results have been cited repeatedly in the NAD+ literature, and more recent clinical observations have echoed them, noting significant improvements in both craving removal and withdrawal symptom relief.
The mechanism likely involves multiple pathways. Restoring NAD+ levels helps neurons produce energy again, which directly affects how the brain processes reward signals. NAD+ also fuels the enzymes responsible for repairing the DNA damage that accumulates during heavy substance use. And because NAD+ supports the production of key neurotransmitters involved in mood and motivation, raising its levels may help rebalance brain chemistry that addiction has disrupted.
How Strong Is the Evidence?
This is where honest caution matters. The clinical evidence for NAD+ in addiction is promising but limited. The 50-patient pilot study produced striking numbers, with craving reduction reaching statistical significance at P values far below the standard threshold. But pilot studies are small by design, and this one lacked a placebo control group, meaning some improvement could reflect the experience of receiving any medical care in a structured setting.
The historical case series from the 1960s is intriguing but predates modern clinical trial standards. No large randomized controlled trials have been completed. The research community has described the data as useful preliminary evidence rather than definitive proof, and most published reviews note that experimental studies remain limited even as clinical reports continue to be positive.
NAD+ is not FDA-approved for addiction treatment. In fact, the FDA has actively issued warning letters to compounding pharmacies producing NAD+ products, stating that NAD+ does not appear on the approved bulk drug substances list for outsourcing facilities. This means the NAD+ infusions available at private clinics exist in a regulatory gray area. They are not illegal for a licensed practitioner to administer, but they have not gone through the formal approval process that would require large-scale safety and efficacy trials.
Oral Supplements vs. IV Infusions
You can also raise NAD+ levels by taking oral precursors, compounds your body converts into NAD+. The two most common are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), widely sold as supplements. These have been shown in other contexts to increase circulating NAD+ levels, but no published clinical trials have tested whether oral precursors produce the same addiction-specific benefits as IV infusions.
The logic behind IV delivery is bioavailability. When NAD+ goes directly into the bloodstream, it bypasses the digestive system entirely, producing a rapid and significant spike in blood levels. Oral precursors raise NAD+ more gradually and to a lesser degree. Whether that slower rise is sufficient to ease withdrawal and reduce cravings is an open question. Most clinics offering NAD+ for addiction use IV protocols, and the existing clinical data applies specifically to that delivery method.
What NAD+ Does Not Replace
NAD+ therapy, even when it works as reported, addresses the biological side of addiction. It does not teach coping skills, resolve trauma, or rebuild relationships. The clinics with the best reported outcomes typically use NAD+ infusions alongside counseling, behavioral therapy, nutritional support, and long-term follow-up. Addiction is a condition with deep psychological and social roots, and no single molecule can substitute for the full spectrum of recovery work. NAD+ may make the early days of sobriety more bearable by reducing the physical misery of withdrawal and the neurological pull of cravings, but sustaining recovery over months and years requires tools that go far beyond what any infusion can provide.